Drug Trial Radar · NCT03242252
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Last checked: Nov 20, 2026Latest source record: Jun 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
787
Actual
Start
Aug 16, 2017
Primary completion
Mar 25, 2019
Study completion Oct 25, 2019
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment. Secondary Objectives: * To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight. * To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.
Conditions
- Type 2 Diabetes Mellitus
- Chronic Kidney Disease Stage 3
Interventions
PlaceboDrug
Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily. Route of administration: Oral
SotagliflozinDrug
Sotagliflozin 200 mg, tablet, orally once daily. Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 26Time frame: Baseline to Week 26
Locations
170 sites in 16 countries. Site status is shown where the registry gives one.
Investigational Site Number 8404018
Birmingham, Alabama
Investigational Site Number 8404045
Guntersville, Alabama
Investigational Site Number 8404004
Phoenix, Arizona
Investigational Site Number 8404022
Phoenix, Arizona
Investigational Site Number 8404007
Little Rock, Arkansas
Investigational Site Number 8404023
Chula Vista, California
Investigational Site Number 8404044
Gold River, California
Investigational Site Number 8404011
Los Angeles, California
Investigational Site Number 8404003
Norco, California
Investigational Site Number 8404025
Northridge, California
Investigational Site Number 8404038
San Dimas, California
Investigational Site Number 8404019
Clearwater, Florida
Investigational Site Number 8404001
DeLand, Florida
Investigational Site Number 8404006
Ocoee, Florida
Investigational Site Number 8404064
Orlando, Florida
Investigational Site Number 8404043
Ormond Beach, Florida
Investigational Site Number 8404013
Palmetto Bay, Florida
Investigational Site Number 8404016
Savannah, Georgia
Investigational Site Number 8404040
Wauconda, Illinois
Investigational Site Number 8404036
Lake Charles, Louisiana
Investigational Site Number 8404020
New Orleans, Louisiana
Investigational Site Number 8404014
Norfolk, Nebraska
Investigational Site Number 8404032
Papillion, Nebraska
Investigational Site Number 8404048
Hackensack, New Jersey
Investigational Site Number 8404074
New York, New York
Investigational Site Number 8404009
The Bronx, New York
Investigational Site Number 8404051
Wilmington, North Carolina
Investigational Site Number 8404028
Winston-Salem, North Carolina
Investigational Site Number 8404029
Winston-Salem, North Carolina
Investigational Site Number 8404026
Dayton, Ohio
Investigational Site Number 8404052
Lansdale, Pennsylvania
Investigational Site Number 8404031
Anderson, South Carolina
Investigational Site Number 8404021
Mt. Pleasant, South Carolina
Investigational Site Number 8404056
Chattanooga, Tennessee
Investigational Site Number 8404015
Austin, Texas
Investigational Site Number 8404050
Austin, Texas
Investigational Site Number 8404060
Austin, Texas
Investigational Site Number 8404005
Beaumont, Texas
Investigational Site Number 8404035
Dallas, Texas
Investigational Site Number 8404039
Houston, Texas
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.